Hyun Gi Noh, MSC

Articles by Hyun Gi Noh, MSC

Real-World Economic Value of a 21-Gene Assay in Early-Stage Breast Cancer

ByStanley E. Waintraub, MD,Donna McNamara, MD,Deena Mary Atieh Graham, MD,Andrew L. Pecora, MD,John Min, BS,Tommy Wu, BA,Hyun Gi Noh, MSC,Jacqueline Connors, RN, OCN,Ruth Pe Benito, MPH, BS,Kelly Choi, MD,Eric Schultz, BS,Stuart L. Goldberg, MD

December 20th 2017

Universal gene expression profiling of patients with stage II breast cancer resulted in outpatient savings of $11,000 (inclusive of testing costs) within 6 months of initiation of medical therapy.

Latest Updated Articles

Real-World Economic Value of a 21-Gene Assay in Early-Stage Breast Cancer
Published: December 20th 2017 | Updated:

Hyun Gi Noh, MSC

Articles by Hyun Gi Noh, MSC

Real-World Economic Value of a 21-Gene Assay in Early-Stage Breast Cancer

Latest Updated Articles

Trending on CGTlive®

CARsgen’s CAR-T Satri-Cel Significantly Reduces CA19-9 Levels in Patients With Pancreatic Ductal Adenocarcinoma

Around the Helix: Cell and Gene Therapy Company Updates – October 22, 2025

AskBio’s Heart Failure Gene Therapy AB-1002 Shows Ability to Improve NYHA Class in Phase 1 Trial

Guess the Therapy Answer October 23, 2025